Johnson & Johnson (J&J) Vision has appointed accomplished ophthalmologist Dr Rajesh Rajpal as its new chief medical officer and global head of clinical and medical affairs.
According to the company, Rajpal has more than 25 years’ experience and joins the company after serving as chief medical officer at Avedro, a company focussing on the field of corneal remodelling that was recently acquired by Glaukos.
Rajpal has specialised in cataract surgery, cornea/external diseases, anterior segment surgery, Lasik, and refractive surgery. As a corneal specialist, he has expertise in the diagnosis and treatment of corneal disease, corneal trauma, and surgical complications. He also has a special interest in the diagnosis and treatment of ocular surface conditions.
For J&J Vision, Rajpal will lead new product development to address unmet needs of patients and eyecare professionals. He will oversee clinical trials and the generation of surgical and vision care evidence, and liaise with government agencies and the academic, scientific, and industry communities.
“We are very pleased to welcome Raj to Johnson & Johnson Vision and are extremely excited to add his expertise and strategic thinking to the business,” said Mr Shlomi Nachman, company group chairman of J&J Vision and the cardiovascular & specialty solutions group.
“His experience as both a practicing ophthalmologist and product development leader will be invaluable as we advance our pipeline of new products and services and seek to provide eye health solutions for everyone around the world.”
Rajpal added: “I am looking forward to guiding and contributing to the continued development of leading-edge products and technology that clinicians, who are my peers, can use to provide the highest level of care to patients globally.”
